0
Abstract: Poster Presentations |

RESISTANCE PHENOTYPES OF STREPTOCOCCUS PNEUMONIAE AND CLINICAL OUTCOME OF RESPIRATORY TRACT INFECTIONS TREATED WITH GEMIFLOXACIN FREE TO VIEW

Ian Morrissey, PhD; Thomas File, MD*; Lionel Mandell, MD; Glenn S. Tillotson, MS
Author and Funding Information

SUMMA Healthcare, Akron, OH


Chest


Chest. 2005;128(4_MeetingAbstracts):371S-c-372S. doi:10.1378/chest.128.4_MeetingAbstracts.371S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  Gemifloxacin (GEM) is a potent fluoroquinolone with excellent activity against respiratory tract infection (RTI) pathogens, including S. pneumoniae (SP). Pooled data from 17 phase III clinical trials for GEM with community-acquired pneumonia, acute bacterial sinusitis & acute exacerbation of chronic bronchitis patients (pts.

METHODS:  530 Pts where SP was the sole pathogen & SP susceptibility known, were evaluated.Clinical success at end of therapy (EOT) & at follow-up (FU, approx. 1-3 weeks after treatment) was studied. Main comparators (CMP) were cefuroxime (61 pts), amoxicillin-clavulanate (37 pts), trovafloxacin (34 pts), cefuroxime & clarithromycin (28 pts), levofloxacin or clarithromycin (11 pts). Percentage success based on susceptibility to penicillin G (Pen) and/or macrolides (Mac) is shown (Table, S = susceptible, NS = non-susceptible, R = resistant, N = pts/group).

RESULTS:  See Table.

CONCLUSION:  GEM showed good clinical success against all resistance phenotypes. These data support the use of GEM in the treatment of RTI, especially where MacR SP prevails.

CLINICAL IMPLICATIONS:  The emergence of antibacterial resistance may effect empirical therapy, gemifloxacin has been shown to be effective against resistant phenotypes of th emost common bacterial respiratory pathogen. PhenotypeTreatment% Success (N)EOTFUAll SPGEM92.5% (321)88.8% (321)CMP90.4% (209)86.0% (207)PenSGEM93.3% (252)88.9% (252)CMP91.0% (166)86.0% (164)PenNSGEM89.7% (68)88.2% (68)CMP88.4% (43)86.0% (43)MacSGEM93.0% (256)88.3% (256)CMP92.0% (175)86.2% (174)MacRGEM90.3% (62)90.3% (62)CMP81.3% (32)83.9% (31)PenR & MacRGEM85.7% (28)85.7% (28)CMP82.4% (17)82.4% (17)

DISCLOSURE:  Thomas File, Consultant fee, speaker bureau, advisory committee, etc. TF & LM are consultants to Oscient.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543